Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Kathryn Shea
A Phase I/Ii Trial of Carfilzomib, Pegylated Liposomal Doxorubicin, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma
Clinical Cancer Research
Cancer Research
Oncology
Related publications
Phase I/Ii Trial of Bendamustine, Ixazomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma
Blood Cancer Journal
Oncology
Hematology
Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Relapsed or Refractory Multiple Myeloma: A Phase 1b Study
American Journal of Hematology
Hematology
Isatuximab Plus Carfilzomib/Dexamethasone Versus Carfilzomib/Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma: IKEMA Phase III Study Design
Future Oncology
Medicine
Cancer Research
Oncology
Carfilzomib for Relapsed or Refractory Multiple Myeloma
The Lancet Oncology
Oncology
Final Overall Survival Results of a Randomized Trial Comparing Bortezomib Plus Pegylated Liposomal Doxorubicin With Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma
Cancer
Cancer Research
Oncology
Multicenter, Phase I, Dose-Escalation Trial of Lenalidomide Plus Bortezomib for Relapsed and Relapsed/Refractory Multiple Myeloma
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
Thalidomide Versus Dexamethasone for the Treatment of Relapsed and/or Refractory Multiple Myeloma: Results From OPTIMUM, a Randomized Trial
Haematologica
Hematology
Emerging Role of Carfilzomib in Treatment of Relapsed and Refractory Lymphoid Neoplasms and Multiple Myeloma
Core Evidence
Medicine
Reviews
References
Pharmacology
A Phase I Trial of Flavopiridol in Relapsed Multiple Myeloma
Cancer Chemotherapy and Pharmacology
Cancer Research
Toxicology
Oncology
Pharmacology